New Treatment Modalities for Geographic Atrophy

Area of Science:

• Ophthalmology
• Retinal Diseases
• Drug Development

Background:

• Age-related macular degeneration (AMD) is a leading cause of vision loss, affecting millions globally.
• Neovascular AMD (nAMD) has seen treatment advances with anti-VEGF drugs, but geographic atrophy (GA) progression remains a significant unmet need.
• Current understanding of GA's molecular and genetic mechanisms drives the development of novel therapies.

Purpose of the Study:

• To review recent clinical trials for novel treatments aimed at slowing geographic atrophy (GA) progression.
• To highlight experimental agents that have undergone significant clinical testing for GA.
• To provide an overview of emerging therapeutic strategies for GA.

Main Methods:

• Literature review of recent clinical trials for geographic atrophy (GA) treatments.
• Focus on agents currently in or completed significant clinical trial phases.
• Analysis of therapeutic targets including complement cascade and neuroprotection.

Main Results:

• Several novel drug classes targeting the complement cascade have shown promising results in clinical trials.
• Neuroprotective agents are also being investigated and demonstrating potential benefits for GA.
• These experimental treatments offer new avenues for managing GA progression.

Conclusions:

• Emerging treatments targeting the complement cascade and neuroprotection represent significant progress in addressing GA.
• These novel therapeutic options hold potential to slow the progression of geographic atrophy (GA).
• Further clinical development is expected to provide new management strategies for this debilitating retinal disease.